20482783

Source:http://linkedlifedata.com/resource/pubmed/id/20482783

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0003872, umls-concept:C0544452, umls-concept:C0681842
pubmed:issue	3
pubmed:dateCreated	2010-7-27
pubmed:abstractText	Since remission is now possible in psoriatic arthritis (PsA) we wished to examine remission rates in PsA patients following anti tumour necrosis factor alpha (TNFalpha) therapy and to examine possible predictors of response.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-10403277, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-10813271, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-10813295, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-12463451, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-1466596, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-14722203, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-16258899, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-16273792, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-16273806, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-16287589, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-16396980, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-16404498, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-16463433, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-16871531, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-17178763, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-17477479, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-17505829, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-18055476, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-18635256, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-18662510, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-19026145, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-19144159, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-20056769, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-2059084, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-3358796, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-8081668, http://linkedlifedata.com/resource/pubmed/commentcorrection/20482783-9010058
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/101154438
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal, Humanized, http://linkedlifedata.com/resource/pubmed/chemical/C-Reactive Protein, http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Tumor Necrosis Factor, http://linkedlifedata.com/resource/pubmed/chemical/TNFR-Fc fusion protein, http://linkedlifedata.com/resource/pubmed/chemical/Tumor Necrosis Factor-alpha, http://linkedlifedata.com/resource/pubmed/chemical/adalimumab, http://linkedlifedata.com/resource/pubmed/chemical/infliximab
pubmed:status	MEDLINE
pubmed:issn	1478-6362
pubmed:author	pubmed-author:BresnihanBarryB, pubmed-author:FearonUrsulaU, pubmed-author:FitzgeraldOliverO, pubmed-author:GrierAlexiaA, pubmed-author:LynchBernadette MBM, pubmed-author:MolloyMarianM, pubmed-author:NgC TCT, pubmed-author:PontifexElizaE, pubmed-author:RenardGuillaumeG, pubmed-author:SaberTajvur PTP, pubmed-author:VealeDouglas JDJ, pubmed-author:WalshCeara A ECA
pubmed:issnType	Electronic
pubmed:volume	12
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	R94
pubmed:dateRevised	2011-11-17
pubmed:meshHeading	pubmed-meshheading:20482783-Adolescent, pubmed-meshheading:20482783-Adult, pubmed-meshheading:20482783-Aged, pubmed-meshheading:20482783-Antibodies, Monoclonal, pubmed-meshheading:20482783-Antibodies, Monoclonal, Humanized, pubmed-meshheading:20482783-Arthritis, Psoriatic, pubmed-meshheading:20482783-Arthritis, Rheumatoid, pubmed-meshheading:20482783-C-Reactive Protein, pubmed-meshheading:20482783-Cohort Studies, pubmed-meshheading:20482783-Disease Progression, pubmed-meshheading:20482783-Female, pubmed-meshheading:20482783-Health Surveys, pubmed-meshheading:20482783-Humans, pubmed-meshheading:20482783-Immunoglobulin G, pubmed-meshheading:20482783-Linear Models, pubmed-meshheading:20482783-Male, pubmed-meshheading:20482783-Middle Aged, pubmed-meshheading:20482783-Outcome Assessment (Health Care), pubmed-meshheading:20482783-Predictive Value of Tests, pubmed-meshheading:20482783-Prospective Studies, pubmed-meshheading:20482783-Receptors, Tumor Necrosis Factor, pubmed-meshheading:20482783-Remission Induction, pubmed-meshheading:20482783-Retrospective Studies, pubmed-meshheading:20482783-Tumor Necrosis Factor-alpha, pubmed-meshheading:20482783-Young Adult
pubmed:year	2010
pubmed:articleTitle	Remission in psoriatic arthritis: is it possible and how can it be predicted?
pubmed:affiliation	Department of Rheumatology, Dublin Academic Medical Centre, St Vincent's University Hospital, and The Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Elm Park, Dublin 4, Ireland.
pubmed:publicationType	Journal Article, Research Support, Non-U.S. Gov't